Epithelial Barrier Dysfunction Module

Immunology Module epithelial_barrier_dysfunction 4 disorders Pathograph 5

A conserved cross-tissue pathophysiology module for the "epithelial barrier hypothesis" of allergic / type 2 inflammatory disease. Epithelial barriers of the skin, airway, gut, and esophagus share critical functions (a physical junctional barrier plus innate immune defense), and in allergic patients — regardless of tissue location — barrier homeostasis is skewed toward loss of terminal differentiation, reduced junctional integrity, and impaired innate defense. The conserved sequence is: an epithelial barrier insult or intrinsic junctional/differentiation defect disrupts the barrier; increased transepithelial allergen and microbial penetration activates innate immunity and antigen-presenting cells; a type 2 (TH2) milieu drives IgE class switch and allergic sensitization; and allergic disease is initiated at the affected barrier and, beyond it, along the atopic march (atopic dermatitis, food allergy, asthma, allergic rhinitis). Conforming disorder nodes substitute the tissue-specific epithelium and lesion (e.g., filaggrin/keratinocyte in atopic dermatitis; bronchial epithelium and tight-junction loss in asthma; squamous esophageal epithelium in eosinophilic esophagitis). This is the cross-tissue counterpart of the gut-specific `intestinal_barrier_dysfunction` module. Key conformance target: `epithelial_barrier_dysfunction#Increased Transepithelial Allergen Penetration and Innate Immune Activation`.

⚙

Pathophysiology Nodes

5 shared nodes are defined in this module.

◉

Cell Types

⇄

Biological Processes

tight junction organization GO:0120193 DECREASED establishment of skin barrier GO:0061436 DECREASED epithelial cell differentiation GO:0030855 DECREASED innate immune response GO:0045087 DECREASED innate immune response GO:0045087 INCREASED type 2 immune response GO:0042092 INCREASED immunoglobulin production GO:0002377 INCREASED

Mechanistic Hypotheses

Epithelial barrier hypothesis of allergic disease

epithelial_barrier_hypothesis CANONICAL Evidence: 1

Evidence balance 1 support

Allergic/type 2 inflammatory diseases share an upstream epithelial barrier defect that, by permitting transepithelial allergen and microbial penetration, initiates type 2 sensitization and allergic disease across tissues. The defect appears to pre-date atopy, implying barrier protection as a prevention target.

↗

Used By Disorder Entries

Asthma via House Dust Mite Allergen Protease-Induced Epithelial Oxidant Signaling → Epithelial Barrier Insult and Junctional Disruption

Atopic Dermatitis via Epidermal Barrier Dysfunction → Epithelial Barrier Insult and Junctional Disruption

Eosinophilic Esophagitis via Esophageal Epithelial Barrier Dysfunction → Epithelial Barrier Insult and Junctional Disruption

Thunderstorm Asthma via Bronchial Epithelial Barrier Dysfunction Facilitating Allergen Access → Increased Transepithelial Allergen Penetration and Innate Immune Activation

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence-backed metadata.

⚙

Pathophysiology

Epithelial Barrier Insult and Junctional Disruption

trigger

External insults (allergen-associated proteases, irritants, pollutants, microbes, mechanical injury) and/or intrinsic defects in barrier components (tight-junction proteins, antiproteases, structural proteins such as filaggrin in the skin) disrupt tight and adherens junctions across barrier epithelia. This is the initiating state shared by skin, airway, gut, and esophageal allergic disease.

epithelial cell CL:0000066 keratinocyte CL:0000312 bronchial epithelial cell CL:0002328

tight junction organization GO:0120193 DECREASED establishment of skin barrier GO:0061436 DECREASED

Used by disorders

Asthma as House Dust Mite Allergen Protease-Induced Epithelial Oxidant Signaling

Atopic Dermatitis as Epidermal Barrier Dysfunction

Eosinophilic Esophagitis as Esophageal Epithelial Barrier Dysfunction

Downstream

Loss of Terminal Differentiation and Reduced Junctional Integrity

Loss of Terminal Differentiation and Reduced Junctional Integrity

amplifier

Across allergic disease, irrespective of the affected organ, the epithelial barrier is skewed toward loss of terminal differentiation, reduced junctional integrity, and impaired innate defense. This dysregulated state appears to pre-date atopy, marking it as a predisposing host trait rather than only a downstream consequence of inflammation.

epithelial cell CL:0000066

epithelial cell differentiation GO:0030855 DECREASED innate immune response GO:0045087 DECREASED

Downstream

Increased Transepithelial Allergen Penetration and Innate Immune Activation

Increased Transepithelial Allergen Penetration and Innate Immune Activation

central effector

With the barrier predisposed to disruption, allergens and microbes gain paracellular access across the epithelium to the underlying lamina propria, where pattern-recognition-receptor signaling and epithelial alarmins drive innate immune activation and antigen-presenting-cell stimulation. This is the central convergence point and the canonical conformance target.

epithelial cell CL:0000066 dendritic cell CL:0000451

innate immune response GO:0045087 INCREASED

Used by disorders

Thunderstorm Asthma as Bronchial Epithelial Barrier Dysfunction Facilitating Allergen Access

Downstream

Type 2 Sensitization and IgE Class Switch

Type 2 Sensitization and IgE Class Switch

effector

The innate-activated, TH2-promoting microenvironment drives T-cell/B-cell interactions in regional lymph nodes that lead to excessive IgE class switch, establishing allergen-specific sensitization characteristic of the allergic diathesis.

T-helper 2 cell CL:0000546 B cell CL:0000236

type 2 immune response GO:0042092 INCREASED immunoglobulin production GO:0002377 INCREASED

Downstream

Allergic Disease Initiation and the Atopic March

Allergic Disease Initiation and the Atopic March

outcome

Barrier-initiated sensitization manifests as allergic disease at the affected barrier (e.g., atopic dermatitis in skin, asthma in airway, eosinophilic esophagitis in esophagus) and can spread systemically to initiate the atopic march — the sequential development of food allergy, asthma, and allergic rhinitis. Because the barrier defect is upstream, barrier-supplementing interventions (e.g., emollients) are proposed primary prevention.

type 2 immune response GO:0042092 INCREASED